Breast Cancer
Clinical research in AR+/HER2-/ER+ breast cancer focuses on patients with locally advanced or metastatic disease, with interest in treatment settings where endocrine and receptor-directed pathways are relevant.
- Hormone receptor-positive disease
- HER2-negative tumours
- Advanced and metastatic breast cancer
The sponsor’s work in this area centres on therapeutic options for difficult-to-treat breast malignancies.
Acute Myeloid Leukaemia and Related Myeloid Neoplasms
Research activity includes acute myeloid leukaemia alongside related myeloid disorders such as myelodysplastic syndrome and chronic myelomonocytic leukaemia, with attention to relapsed, refractory, and newly diagnosed disease.
- Relapsed or refractory AML
- Myelodysplastic syndrome
- Chronic myelomonocytic leukaemia
These studies reflect a therapeutic focus on haematological malignancies with high unmet need.
RET-Altered Malignancies
The sponsor is active in cancers driven by RET gene alterations, including RET fusion-positive non-small cell lung cancer and other advanced solid tumours with abnormal RET signalling.
- RET-altered tumours
- RET fusion-positive NSCLC
- Advanced solid tumours
Research in this domain is directed toward targeted treatment strategies for oncogenic driver alterations.
Combination Oncology Therapy
Several trials examine combination cancer therapy across haematologic and solid tumours, with interest in pairing investigational agents with established anti-cancer treatments.
- BCL-2 inhibition
- Hypomethylating agents
- Combination regimens in oncology
This includes research in settings where multi-agent treatment is relevant to treatment-resistant disease.
